Verrica Pharmaceuticals Inc

NASDAQ:VRCA  
9.35
-0.10 (-1.06%)
Products, Regulatory, Earnings Announcements

Verrica Pharmaceuticals Announces Positive Topline Results In Phase 2 Clinical Study Of VP-102 In Patients With External Genital Warts

Published: 11/10/2020 13:08 GMT
Verrica Pharmaceuticals Inc. (VRCA) - Verrica Pharmaceuticals Announces Positive Topline Results in Phase 2 Clinical Study of Vp-102 in Patients With External Genital Warts (care-1).
Verrica Pharmaceuticals Inc - Vp-102 Was Well-tolerated With No Reported Serious Adverse Events Related to Vp-102.
Verrica Pharmaceuticals Inc - 35% of Subjects Treated With Vp-102 Achieved Complete Clearance of All Treatable Genital Warts Versus 2.4% for Vehicle.
Verrica Pharmaceuticals Inc - Based on Positive Outcome, Verrica Will Request an End-of-phase 2 Meeting With FDA.
Verrica Pharmaceuticals Inc - Vp-102 Achieved Positive Results on Both Primary Endpoint and Secondary Endpoint.
Verrica Pharmaceuticals Inc - Intend to Request an End-of-phase 2 Meeting With FDA for Treatment of Egw in Q1 of 2021.
Revenue is expected to be $0 Million
Adjusted EPS is expected to be -$0.40

Next Quarter Revenue Guidance is expected to be $0 Million
Next Quarter EPS Guidance is expected to be -$0.40

More details on our Analysts Page.